A Clinical Trial to Evaluate the Effects of a Supplement on Cognitive Function and Energy Levels
5 août 2026 mis à jour par: Artah Nutrition Limited
This study evaluates the effects of Artah's Cellular Hydration electrolyte supplement on cognitive function and energy levels in healthy adults aged 25-60 who experience mild to moderate fatigue, brain fog, or related symptoms. The trial is a single-arm, unblinded, virtual study in which all 50 participants will use the test product daily for 4 weeks.
Participants will complete self-reported questionnaires at Baseline, Week 1, Week 2, Week 3, and Week 4, and will undergo cognitive battery testing at Baseline and Week 4. The primary endpoint is change in cognitive performance scores as measured by a standardized cognitive battery. Secondary endpoints include participants' self-reported perceptions of mental clarity, alertness, mood, physical performance, overall energy levels, and frequency of food cravings.
Aperçu de l'étude
Statut
Complété
Les conditions
Intervention / Traitement
Type d'étude
Interventionnel
Inscription (Réel)
50
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
Nevada
-
Las Vegas, Nevada, États-Unis, 89101
- Citruslabs
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
Accepte les volontaires sains
Oui
La description
Inclusion Criteria:
- Be male or female.
- Be aged 25-60.
- Anyone currently experiencing mild to moderate issues with at least three of the following: low energy or fatigue
- difficulty concentrating or low mental sharpness
- experiences of brain fog or lack of mental clarity
- feeling of low productivity
- muscle weakness
- unwanted food cravings.
- Undertakes moderate to high-intensity exercise such as jogging/running and/or heavy resistance training at least three times per week.
- Willing to refrain from taking any products, medications, or supplements that target energy, cognition, or physical performance during the test period.
- Anyone with a BMI 18.5 to 30.
- Anyone who has access to a device (e.g., smartphone, laptop, computer) for reliable internet.
- Anyone who is generally healthy - does not live with any uncontrolled chronic disease.
- Anyone willing to maintain a consistent diet and physical activity throughout study duration.
Exclusion Criteria:
- Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
- Anyone suffering from gastrointestinal disorders including but not limited to small intestinal bacterial overgrowth (SIBO), irritable bowel syndrome (IBS), and celiac disease.
- Anyone suffering from hyperkalemia (high potassium), liver disease, or kidney disease.
- Anyone taking ACE inhibitors or potassium-sparing diuretics, examples include: Spironolactone (Aldactone), Eplerenone (Inspra), Amiloride (Midamor), Triamterene (Maxzide), Lisinopril (Zestril, Prinivil), Enalapril (Vasotec), Ramipril (Altace), Benazepril (Lotensin), Quinapril (Accupril), Losartan (Cozaar), Valsartan (Diovan), Olmesartan (Benicar), Irbesartan (Avapro), Lithium carbonate (Lithobid, Eskalith).
- Anyone taking antibiotics.
- Anyone with any allergies or sensitivities to any of the study product ingredients.
- Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period).
- Anyone unwilling to follow the study protocol.
- Anyone with a history of substance abuse.
- Anyone who is a shift worker with an irregular sleep-wake cycle.
- Anyone who drinks heavily (8 or more alcoholic drinks per week for women or 15 or more alcoholic drinks per week for men).
- Anyone who is currently a smoker or has been a smoker in the past 3 months.
- Currently partaking in another research study, or planning to at any point during this study's duration.
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Cellular Hydration Supplement
|
All 50 participants receive the Artah Cellular Hydration electrolyte supplement taken twice daily (once in the morning before the first meal and once in the afternoon after lunch or before evening exercise) as one teaspoon (approximately 7 g) stirred into 750 ml of water for 4 weeks.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Cognitive Battery Test Score (Polygons)
Délai: Baseline and Week 4
|
Change in processing speed and information sorting ability assessed via the Polygons timed cognitive battery subtest
|
Baseline and Week 4
|
|
Change in Cognitive Battery Test Score (Double Trouble)
Délai: Baseline and Week 4
|
Change in selective attention and processing speed assessed via the Double Trouble timed cognitive battery subtest (Stroop-based)
|
Baseline and Week 4
|
|
Change in Cognitive Battery Test Score (Feature Match)
Délai: Baseline and Week 4
|
Change in focus and processing speed assessed via the Feature Match timed cognitive battery subtest
|
Baseline and Week 4
|
|
Change in Cognitive Battery Test Score (Paired Associates)
Délai: Baseline and Week 4
|
Change in memory recall assessed via the Paired Associates performance-based cognitive battery subtest
|
Baseline and Week 4
|
|
Change in Cognitive Battery Test Score (Digit Span)
Délai: Baseline and Week 4
|
Change in short-term memory and cognitive flexibility assessed via the Digit Span performance-based cognitive battery subtest
|
Baseline and Week 4
|
|
Change in Cognitive Battery Test Score (Spatial Planning)
Délai: Baseline and Week 4
|
Change in executive function and logical decision-making assessed via the Spatial Planning timed cognitive battery subtest
|
Baseline and Week 4
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Self-Reported Mental Clarity and Focus
Délai: Baseline, Week 1, Week 2, Week 3, and Week 4
|
Assessed via self-reported questionnaire
|
Baseline, Week 1, Week 2, Week 3, and Week 4
|
|
Change in Self-Reported Alertness
Délai: Baseline, Week 1, Week 2, Week 3, and Week 4
|
Assessed via self-reported questionnaire
|
Baseline, Week 1, Week 2, Week 3, and Week 4
|
|
Change in Self-Reported Mood
Délai: Baseline, Week 1, Week 2, Week 3, and Week 4
|
Assessed via self-reported questionnaire
|
Baseline, Week 1, Week 2, Week 3, and Week 4
|
|
Change in Self-Reported Physical Performance
Délai: Baseline, Week 1, Week 2, Week 3, and Week 4
|
Assessed via self-reported questionnaire
|
Baseline, Week 1, Week 2, Week 3, and Week 4
|
|
Change in Self-Reported Overall Energy Levels
Délai: Baseline, Week 1, Week 2, Week 3, and Week 4
|
Assessed via self-reported questionnaire
|
Baseline, Week 1, Week 2, Week 3, and Week 4
|
|
Change in Self-Reported Frequency of Food Cravings
Délai: Baseline, Week 1, Week 2, Week 3, and Week 4
|
Assessed via self-reported questionnaire
|
Baseline, Week 1, Week 2, Week 3, and Week 4
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Collaborateurs
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
13 juin 2025
Achèvement primaire (Réel)
16 août 2025
Achèvement de l'étude (Réel)
16 août 2025
Dates d'inscription aux études
Première soumission
5 août 2026
Première soumission répondant aux critères de contrôle qualité
5 août 2026
Première publication (Réel)
10 août 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
10 août 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
5 août 2026
Dernière vérification
1 août 2026
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 20772
- legacy-20772
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .